Medical - Devices
Compare Stocks
2 / 10Stock Comparison
ADGM vs MEDP
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
ADGM vs MEDP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| Market Cap | $15M | $12.24B |
| Revenue (TTM) | $-143K | $2.68B |
| Net Income (TTM) | $-75M | $460M |
| Gross Margin | -6.2% | 29.1% |
| Operating Margin | -232.3% | 21.0% |
| Forward P/E | — | 25.2x |
| Total Debt | $16M | $250M |
| Cash & Equiv. | $21M | $497M |
ADGM vs MEDP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 24 | May 26 | Return |
|---|---|---|---|
| Adagio Medical Hold… (ADGM) | 100 | 18.5 | -81.5% |
| Medpace Holdings, I… (MEDP) | 100 | 120.7 | +20.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADGM vs MEDP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ADGM is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.87
- Lower volatility, beta 0.87, Low D/E 81.7%, current ratio 3.27x
- Beta 0.87, current ratio 3.27x
MEDP carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
- 14.4% 10Y total return vs ADGM's -89.5%
- 20.0% revenue growth vs ADGM's -10.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs ADGM's -10.3% | |
| Quality / Margins | 17.2% margin vs ADGM's -199.9% | |
| Stability / Safety | Beta 0.87 vs MEDP's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +42.9% vs ADGM's -26.1% | |
| Efficiency (ROA) | 24.8% ROA vs ADGM's -189.8% |
ADGM vs MEDP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ADGM vs MEDP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MEDP leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MEDP and ADGM operate at a comparable scale, with $2.7B and -$143,000 in trailing revenue. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to ADGM's -199.9%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | -$143,000 | $2.7B |
| EBITDAEarnings before interest/tax | -$67M | $577M |
| Net IncomeAfter-tax profit | -$75M | $460M |
| Free Cash FlowCash after capex | -$24M | $745M |
| Gross MarginGross profit ÷ Revenue | -6.2% | +29.1% |
| Operating MarginEBIT ÷ Revenue | -232.3% | +21.0% |
| Net MarginNet income ÷ Revenue | -199.9% | +17.2% |
| FCF MarginFCF ÷ Revenue | -115.6% | +27.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +26.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -106.3% | +16.6% |
Valuation Metrics
ADGM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $15M | $12.2B |
| Enterprise ValueMkt cap + debt − cash | $10M | $12.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.27x | 28.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.24x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.88x |
| EV / EBITDAEnterprise value multiple | — | 21.31x |
| Price / SalesMarket cap ÷ Revenue | 54.49x | 4.84x |
| Price / BookPrice ÷ Book value/share | 0.73x | 27.57x |
| Price / FCFMarket cap ÷ FCF | — | 17.96x |
Profitability & Efficiency
MEDP leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-8 for ADGM. MEDP carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADGM's 0.82x. On the Piotroski fundamental quality scale (0–9), MEDP scores 6/9 vs ADGM's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -7.5% | +120.9% |
| ROA (TTM)Return on assets | -189.8% | +24.8% |
| ROICReturn on invested capital | — | +154.9% |
| ROCEReturn on capital employed | -374.1% | +65.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.82x | 0.55x |
| Net DebtTotal debt minus cash | -$4M | -$247M |
| Cash & Equiv.Liquid assets | $21M | $497M |
| Total DebtShort + long-term debt | $16M | $250M |
| Interest CoverageEBIT ÷ Interest expense | -36.69x | — |
Total Returns (Dividends Reinvested)
MEDP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MEDP five years ago would be worth $25,938 today (with dividends reinvested), compared to $1,053 for ADGM. Over the past 12 months, MEDP leads with a +42.9% total return vs ADGM's -26.1%. The 3-year compound annual growth rate (CAGR) favors MEDP at 27.0% vs ADGM's -52.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -11.8% | -24.9% |
| 1-Year ReturnPast 12 months | -26.1% | +42.9% |
| 3-Year ReturnCumulative with dividends | -89.5% | +104.6% |
| 5-Year ReturnCumulative with dividends | -89.5% | +159.4% |
| 10-Year ReturnCumulative with dividends | -89.5% | +1442.7% |
| CAGR (3Y)Annualised 3-year return | -52.8% | +27.0% |
Risk & Volatility
Evenly matched — ADGM and MEDP each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADGM is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than MEDP's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MEDP currently trades 68.2% from its 52-week high vs ADGM's 36.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.26x |
| 52-Week HighHighest price in past year | $2.58 | $628.92 |
| 52-Week LowLowest price in past year | $0.74 | $284.48 |
| % of 52W HighCurrent price vs 52-week peak | +36.9% | +68.2% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 40.6 |
| Avg Volume (50D)Average daily shares traded | 124K | 371K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $498.86 |
| # AnalystsCovering analysts | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +7.5% |
MEDP leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ADGM leads in 1 (Valuation Metrics). 1 tied.
ADGM vs MEDP: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ADGM or MEDP a better buy right now?
For growth investors, Medpace Holdings, Inc.
(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). Medpace Holdings, Inc. (MEDP) offers the better valuation at 28. 1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Medpace Holdings, Inc. (MEDP) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADGM or MEDP?
Over the past 5 years, Medpace Holdings, Inc.
(MEDP) delivered a total return of +159. 4%, compared to -89. 5% for Adagio Medical Holdings, Inc. (ADGM). Over 10 years, the gap is even starker: MEDP returned +1443% versus ADGM's -89. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADGM or MEDP?
By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.
(ADGM) is the lower-risk stock at 0. 87β versus Medpace Holdings, Inc. 's 1. 26β — meaning MEDP is approximately 44% more volatile than ADGM relative to the S&P 500. On balance sheet safety, Medpace Holdings, Inc. (MEDP) carries a lower debt/equity ratio of 55% versus 82% for Adagio Medical Holdings, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ADGM or MEDP?
By revenue growth (latest reported year), Medpace Holdings, Inc.
(MEDP) is pulling ahead at 20. 0% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: Adagio Medical Holdings, Inc. grew EPS 27. 2% year-over-year, compared to 21. 0% for Medpace Holdings, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ADGM or MEDP?
Medpace Holdings, Inc.
(MEDP) is the more profitable company, earning 17. 8% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — MEDP leads at 30. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ADGM or MEDP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ADGM or MEDP better for a retirement portfolio?
For long-horizon retirement investors, Medpace Holdings, Inc.
(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Both have compounded well over 10 years (MEDP: +1443%, ADGM: -89. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ADGM and MEDP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ADGM is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.